A cream result cannot be borrowed to support an injection. GHK-Cu has product-specific skin and wound reports, while the human scalp-injection report used a mixture. FDA’s non-injectable Category 1 entry also does not cover injection [3].
Evidence and regulation both depend on the route
Many sellers present the cream and the injection as two versions of one product. FDA doesn't. Its compounding list splits GHK-Cu by route, and the split decides what a pharmacy may legally make. The evidence splits the same way. Nearly all human data are for skin and wounds, and almost none are for injection.
Separate three questions: what the exact product has been tested for, whether its commercial supply satisfies applicable law, and whether the result is relevant to your intended use. Category 1 alone cannot answer all three.
FDA treats each route differently
FDA's 503A list, updated May 14, 2026, puts "GHK-Cu (except for injectable routes of administration)" in Category 1 [3]. Category 1 means FDA is still evaluating the substance and doesn't intend to act against licensed pharmacies that compound it under its interim policy [4]. That is a temporary enforcement position, not an approval.
Injectable GHK-Cu is in no category at all. FDA’s current categories document records withdrawn nominations and restores only the non-injectable entry [5]. That withdrawal does not authorize routine commercial bulk compounding. Authorized clinical investigation is a separate legal framework, not retail permission.
| Topical (cream, serum, foam) | Injected | |
|---|---|---|
| FDA status | Category 1 when compounded (under evaluation); cosmetics generally need no premarket approval, except certain color additives | Not covered by the non-injectable Category 1 policy |
| Human research | Small, heterogeneous topical studies | Isolated injected benefit not established |
| Safety concern FDA has stated | None stated for non-injectable routes | Possible immune reactions from aggregation; peptide-related impurities |
| Offered by telehealth providers this site checks | Yes, as compounded creams or foam | Not covered on this page |
| What a result would tell you | Effects on the skin surface | Isolated systemic benefit not established |
Sources: FDA 503A list (May 14, 2026); FDA safety-risks page (April 22, 2026); PubMed.
The dates matter because GHK-Cu's status moved twice in 2026. The full record is on is GHK-Cu FDA-approved.
Topical GHK-Cu has a small amount of human evidence
Two older controlled reports illustrate distinct clinical settings. The ulcer abstract does not state enrollment; neither establishes everyday anti-aging benefit.
The first followed laser resurfacing around the mouth. Patients were randomized to skin care with or without GHK-Cu, and 13 finished the study [7]. Blinded evaluators and computer analysis found no difference in how fast redness cleared or in wrinkle improvement. Patients using GHK-Cu did rate their skin quality higher on a questionnaire.
The second was a multicenter, evaluator-blinded trial of a GHK-Cu gel on diabetic foot ulcers, against an inactive gel [8]. Median wound closure was 98.5% with GHK-Cu against 60.8% with the inactive gel, and infections were less common. That was a prescription-style wound treatment tested in 1994. It wasn't a cosmetic serum.
What the skin trials do and don't show for wrinkles, firmness and hair is covered claim by claim in does topical GHK-Cu work and does GHK-Cu work.
Newer topical reports answer narrower questions
A 40-person nonrandomized acne-scar study added copper peptide to dermarolling. Later between-group differences were not significant; hyperpigmentation occurred in 8 of 20 combination patients versus none with dermarolling alone. Allocation and baseline imbalance limit interpretation [1].
A preliminary 18-person randomized split-face report found eyebrow-count and diameter improvements after 12 weeks. Eyebrows, scalp hair and systemic injection claims are different questions; this result cannot answer them all [2].
Isolated injected GHK-Cu lacks established controlled benefit
The reviewed PubMed sources do not establish controlled benefit from isolated injected GHK-Cu [11]. The papers that come up are animal wound studies, lab work and injectable gels in development. FDA's own description is that human data are limited [5].
The nearest human report is a 2018 open-label study of scalp injections for hair loss [9]. The formula had six ingredients: several growth factors, thymosin beta-4 and copper tripeptide-1. There was no comparison group, so any effect can't be credited to GHK-Cu, or to any one ingredient.
Claims that injection works "better" because it bypasses the skin rest on reasoning, not results. The mixed-ingredient scalp report measured outcomes in people, but cannot isolate injected GHK-Cu or establish systemic benefit.
FDA's stated risks are for the injected route
FDA's concern about injectable GHK-Cu is specific. Compounded injections "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities" [5]. In plain terms, peptide clumps or contaminants could provoke an immune reaction, and there's little human data to judge how often.
FDA has stated no comparable risk for non-injectable routes. That isn't the same as a clean safety record, since topical products have their own questions about irritation and copper exposure. Those are covered in is GHK-Cu safe.
Can GHK-Cu be injected into the face?
The reviewed FDA lists do not establish a routine commercial bulk-compounding basis for injectable GHK-Cu [3]. This is distinct from an authorized clinical investigation; an unapproved product cannot be justified simply by calling it research.
If you're considering facial treatments, a dermatologist can walk you through FDA-approved options and what each has been tested for.
What to check on a topical GHK-Cu product
Topical GHK-Cu comes two ways, and the rules differ. A cosmetic serum sold for appearance generally needs no premarket approval, except for certain color additives before it goes on sale [6]. A compounded cream sold by prescription is made by a pharmacy under the Category 1 policy. Whether a product counts as a cosmetic or a drug depends on its intended use, including the claims made for it.
- Is it a cosmetic or a prescription product? The label and the seller's own pages should say.
- Is the strength stated? A product that won't say how much GHK-Cu it contains can't be compared.
- For a prescription product, is the compounding pharmacy named?
- Does a cosmetic make drug claims, such as healing or regenerating tissue? Under FDA's rules, those claims make it a drug.
The reviewed reports do not compare routes directly
The reviewed sources identify no head-to-head trial of topical and injected GHK-Cu. The topical trials measured skin and wound healing; the one injection report studied a six-ingredient hair formula. Those outcomes don't line up, so neither route's results can be borrowed for the other.
How much a cream reaches beyond the skin is also unsettled. In a 2010 lab study using donated human skin, copper from GHK-Cu passed through the skin layers and some stayed in the tissue [10]. The reviewed sources do not establish blood levels of intact GHK-Cu after ordinary cream use.
That leaves a simple rule of thumb. If a claim comes from a cream trial, it's about creams. If it comes from an injection, there isn't a controlled trial yet.
Category 1 describes a conditional interim enforcement policy; other legal requirements still apply. It is not a finding that a particular compounded product is safe, effective or lawfully supplied in every circumstance. Product-specific pharmacy and plan questions are explained in how we check providers.